Amryt Pharma
Dublin
About Amryt Pharma
Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S. Amryt’s earlier-stage products are focussed on developing novel, next-generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there are high unmet medical needs. These include acromegaly and Cushing's disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $186.3M
- Funding stage: M&A
- Last round: Post-IPO Debt (Feb 2022)
- Ticker: lse:AMYT
- Website: amrytpharma.com
- Phone: [email protected]
Industries & Categories
Biopharma, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/amryt-pharma-109677 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.